{"name":"Tasly Tianjin Biopharmaceutical Co., Ltd.","slug":"tasly-tianjin-biopharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ETV or TDF","genericName":"ETV or TDF","slug":"etv-or-tdf","indication":"HIV-1 infection","status":"phase_2"}]}],"pipeline":[{"name":"ETV or TDF","genericName":"ETV or TDF","slug":"etv-or-tdf","phase":"phase_2","mechanism":"Inhibits viral replication","indications":["HIV-1 infection"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNYk5fUTdiZXJyZXNiS3ZQc1ZYRldqQ1BKQ2tEcVdqRlZ1U0o2dzNLSEwyU2o3czBDVnpKWC1aYnFJMVNUZ0hDZFRpS2trZGpzUGRJcXltYXoxYWdaLXhzems0VG1ObS1sRzdmUmJ1OFpnSHVwcXpCQXlvdVcxcjJOTWlVTHllcFZRWWItWGJneXI3cGdVb3lXS0RRRktkS0xYMGNqcTY2eXRWTHBTM0NrTGJvRjN6a2ctZWlKTzQyZFZMNWlTWDU1SzZINjh4bVdOVkUxMHhhSjAzX2QxZWMxUDM3MUxSbXVmdkJ2aFhZWGRKbU5IR19kVTN2WVJOSTZkOHpRWWdoVnFFTnNhaGc?oc=5","date":"2026-04-07","type":"trial","source":"Barchart.com","summary":"Hepatitis B Virus Infection Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com","headline":"Hepatitis B Virus Infection Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Trea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQR0lrTk5nY29ZV28xWnVvNGxlODVDX2tQOFFBbDVORXV1bWhBTkpwWVM4YTl0dWxOdU82UTF5WHVRNmdjaElya0pMd0JNSmVzXzR1RG1VdV9QbnBfQkhTVi12d0ZWbWo1RldPOFZPVjlDMjZTNUswRWc0WEJXOHMwaEs0c3FwV25RYzgzUVdIVDktY2hwSFZuQk5EMkdGd2JBbXc5TTEwczZGMlU5aUdRLUM3TTJDcnVDSmdOTHJpeEhFb1R5cFFkQzgxQ0xhLUNBM0w4RHp3TEtva1JEZE4yMk1EbXJqdXhpdHd3N20tNk1pcEJINmc?oc=5","date":"2025-09-04","type":"earnings","source":"citynewsservice.cn","summary":"First-half earnings a bitter pill for many companies selling traditional Chinese medicine - citynewsservice.cn","headline":"First-half earnings a bitter pill for many companies selling traditional Chinese medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNMjVkdDZGZ1hUMURQVWczOWVkSkNGeUd5WVkyUXRKeGJCZWFPYkRsM1Z0bFh3MC1CRTB5b2ExNDh6UV9OTllObHZhN0JYbGZFN3Jpc0E5RFBkMmZNUzZad0lOaHdqdklLQUtVbVF1VmRZdzVBOWFuZzdFYVNpS2ppVk1FanFYU0VEZXhRaHhXM0g1MDctb0xWTTB4VXd1dFl1U0NBS3BERTRGZm1fSTlMVEJfNkN6Q1FqVzYwblFfOXE4VW9kdmhhdlc5QjJCam5BX3MwMkoyakNkOFYyelkxV0VR?oc=5","date":"2025-06-17","type":"pipeline","source":"PR Newswire","summary":"Chronic Hepatitis B Market--The US to Have the Lion's Share Among the 7MM, Predicts DelveInsight - PR Newswire","headline":"Chronic Hepatitis B Market--The US to Have the Lion's Share Among the 7MM, Predicts DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOX2xMdVlLZXJlQjY4bWVCQnBoWGdoa0JPNE1mVG5KbjNuYTZabnJoVG9yWnRaU1RRM2tMZGFHMEF1Z0NuMXpqa3hfNUtXelNaWXNtOW9WSWt1cU02RXlVemwtR2JVVEVjcTUtNVR6aXlsM3ByU0hjUktBeUtiS1hGV0FOY2VrY3Z2VXlHVHZLOUxoMjlSYWU4TjRNX2JrOTBBSjFfeUE5Z0wxcEV3SDZZZ1J2N0JwRzZubTJ0SklzbFlWVThhbC16ZFVUT2J6UTRySmxmSnRwVQ?oc=5","date":"2025-03-05","type":"pipeline","source":"PR Newswire","summary":"Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight - PR Newswire","headline":"Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE0wR1ViZ0Z4OHpfOEU2UVJWX0o2UUlzZjFxV0E1OEVvZzItVVRTR1hXME9TNmx3QkVBUjM5UlhNNG1zVFVHaDBNU2tLYkFCdWU5YnhHX2pEeTNKR1dIV0JzQi10WmYyOU5RSXF0cGU1X0VOV28?oc=5","date":"2015-08-19","type":"pipeline","source":"China Daily","summary":"Getting TCM accepted in US - China Daily","headline":"Getting TCM accepted in US","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}